Raseglurant

Raseglurant (also known as MK-0517) is a drug that acts as an antagonist for the metabotropic glutamate receptor 5 (mGluR5). It was developed by Merck & Co. for the treatment of migraine and irritable bowel syndrome (IBS), but development was discontinued after Phase II clinical trials.

History

Raseglurant was first synthesized and developed by Merck & Co., a multinational pharmaceutical company. The drug was initially developed for the treatment of migraine and irritable bowel syndrome. However, the development was discontinued after Phase II clinical trials due to lack of efficacy.

Pharmacology

Raseglurant is an antagonist for the metabotropic glutamate receptor 5 (mGluR5). Glutamate is the main excitatory neurotransmitter in the brain, and mGluR5 is one of the receptors that it acts upon. By blocking this receptor, raseglurant can potentially reduce the overactivity of glutamate that is associated with conditions such as migraine and IBS.

Clinical Trials

Raseglurant underwent Phase II clinical trials for the treatment of migraine and IBS. However, the trials did not show sufficient efficacy of the drug for these conditions, and its development was subsequently discontinued.

Potential Uses

Despite the discontinuation of its development, raseglurant has been the subject of research for potential use in other conditions. These include Parkinson's disease, schizophrenia, and anxiety disorders, where overactivity of glutamate and mGluR5 is also thought to play a role.

See Also

• Metabotropic glutamate receptor
• Glutamate (neurotransmitter)
• Migraine
• Irritable bowel syndrome
• Parkinson's disease
• Schizophrenia
• Anxiety disorder